Dynavax, AstraZeneca ink $136M deal

Dynavax Technologies has inked a collaboration deal with the UK's AstraZeneca to develop new TLR-9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. Dynavax gains $10 million up front, research funds and preclinical milestones that could raise its committed financing to $27 million. The total package is worth up to $136 million for Dynavax.

"We believe that AstraZeneca is the ideal partner for the development of asthma and COPD ISS-based therapies, as they have one of the most widely respected and commercially successful respiratory product portfolios in the industry," said Dr. Dino Dina, Dynavax's chief executive, in a statement.

- see the release on the pact

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.